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support of African farmers will 
help in the long run.
Fifth, investments in efforts to 
combat the global epidemics of 
AIDS and tuberculosis are much 
more generous than they were 
five years ago, but funding must 
be increased and sustained if we 
are to slow these increasingly com-
plex epidemics. One of the most 
ominous recent developments is 
the advent of highly drug-resistant 
strains of both causative patho-
gens. “Extensively drug-resistant 
tuberculosis” has been reported in 
the United States, Eastern Europe, 
Asia, South Africa, and elsewhere; 
in each of these settings, the 
copresence of HIV has amplified 
local epidemics of these almost 
untreatable strains. Drug-resistant 
malaria is now common world-
wide, extensively drug-resistant 
HIV disease will surely follow, 
and massive efforts to diagnose 
and treat these diseases ethi-
cally and effectively will be need-
ed. We have already learned a 
great deal about how best to ex-
pand access to second-line anti-
tuberculous drugs while increas-
ing control over their use5; these 
lessons must be applied in the 
struggles against AIDS, malaria, 
and other infectious pathogens.
Finally, there is a need for a 
renewed basic-science commit-
ment to vaccine development, more 
reliable diagnostics (the 100-year-
old tests widely used to diagnose 
tuberculosis are neither specific 
nor sensitive), and new classes of 
therapeutics. The research-based 
pharmaceutical industry has a 
critical role to play in drug devel-
opment, even if the overall goal 
is a segmented market, with high-
er prices in developed countries 
and generic production with af-
fordable prices in developing coun-
tries.
There has been a heartening in-
crease in basic-science investments 
for tuberculosis and malaria; fund-
ing for HIV research at the Na-
tional Institutes of Health remains 
robust. Yet the fruits of such re-
search will not arrive in time for 
those now living with, and dying 
from, AIDS and tuberculosis. New 
tools to prevent, diagnose, and 
treat the diseases of poverty will 
be added to the stockpile of other 
potentially lifesaving products that 
do not reach the poorest people, 
unless we develop an equity plan 
to provide them. Right now, our 
focus must be on improving ac-
cess to the therapies that are avail-
able in high-income countries. 
The past few years have shown us 
that we can make these services 
available to millions, even in the 
poorest reaches of the world.
The unglamorous and diffi-
cult process of increasing access 
to prevention and care needs to 
be our primary focus if we are to 
move toward the lofty goal of eq-
uitably distributed medical ser-
vices in a world riven by inequal-
ity. Without such goals, the slogan 
“One World, One Hope” will re-
main nothing more than a dream.
An interview with Dr. Farmer can be heard at 
www.nejm.org. 
Dr. Kim is chief of the Division of Social Med-
icine and Health Inequalities at Brigham and 
Women’s Hospital, and Dr. Farmer is a pro-
fessor of social medicine at Harvard Medical 
School; both are former directors of Partners 
in Health, all in Boston.
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aids in 2006 — moving toward one world, one hope?
Changing the Paradigm for HIV Testing — 
The End of Exceptionalism
Ronald Bayer, Ph.D., and Amy L. Fairchild, Ph.D., M.P.H.
The Centers for Disease Con-trol and Prevention (CDC) is 
poised to issue new recommen-
dations for testing for HIV in 
adults, adolescents, and pregnant 
women. Frustrated that more than 
25 percent of Americans with HIV 
infection are unaware of their sta-
tus and that almost 40 percent of 
those with newly diagnosed AIDS 
discover that they are infected less 
than a year before diagnosis, of-
ficials have proposed that HIV 
screening be routinely offered in 
all health care settings.
The CDC already recommends 
routine testing among high-risk 
groups and in high-prevalence set-
tings. The radical departure is the 
extension of routine testing to the 
entire population and the recon-
ceptualization of the requirements 
for consent. Patients would be told 
that HIV testing was a routine part 
of care and given the opportunity 
to opt out. According to the CDC, 
specific signed consent would no 
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longer be required, because “gen-
eral consent for medical care is 
sufficient to encompass consent 
for HIV testing.”
These proposals are similar to 
those offered by New York City’s 
commissioner of health, Thomas 
Frieden, who has called for elim-
inating the requirements for pre-
test counseling and written in-
formed consent that have been in 
place since 1988 and replacing the 
requirement for consent with the 
right to opt out. In a recent cir-
cular about informed consent, the 
New York City health department 
recommended that physicians say 
to their patients, in advising them 
about all the blood tests that 
will be performed, “I am going 
to . . . do an HIV test. Do you 
have any questions?”1 Inevitably, 
the effects of such challenges to 
the status quo will be felt through-
out the country, in health depart-
ments, hospitals, and other clin-
ical settings.
These moves signal the end of 
the exceptionalism that has dis-
tinguished public health policy 
with regard to AIDS from ap-
proaches to other communicable 
and sexually transmitted diseas-
es.2 Against a backdrop of fear, 
stigma, and relative clinical pow-
erlessness, AIDS activists and their 
public health allies initially sought 
approaches that would respect the 
autonomy and privacy rights of 
people with or at risk for HIV in-
fection and that would offer pro-
tection from unwarranted dis-
crimination. Avoiding compulsory 
measures such as isolation and 
quarantine, which were so much 
a part of the public health tradi-
tion, was all the more crucial, 
since the people with increased 
risk — gay and bisexual men, drug 
users, and their sexual partners 
— were already socially vulner-
able. As then–Surgeon General 
C. Everett Koop often said, poli-
cies and practices that appeared to 
threaten such persons could only 
drive the epidemic underground 
and make it more difficult to work 
with the populations within which 
HIV was spreading.
The exceptionalist perspective 
was reflected in policies on sur-
veillance and partner notification, 
but it was strongest in the con-
text of HIV testing. From 1985, 
when the HIV antibody test be-
came available, fear about discrim-
ination and stigmatization, con-
cern about the potentially severe 
psychological burden of an HIV 
diagnosis in the absence of effec-
tive therapy, and skepticism about 
the relationship between testing 
and the changing of risky be-
havior led AIDS activists to warn 
about the dangers of the test. Pub-
lic health officials, in contrast, 
saw the voluntary testing and 
counseling of people at high risk 
as the core feature of a preven-
tive public health strategy. Out of 
the ensuing bitter conflict emerged 
some exacting standards for spe-
cific written consent and require-
ments for pretest counseling. This 
approach was markedly different 
from what typically happened in 
clinical settings, where physicians 
ordered blood work for patients 
who were generally unaware of 
what was being tested for and 
consent was assumed.
In the late 1980s, as clinicians 
gained greater confidence in their 
ability to manage HIV disease, 
they began to bridle under the ex-
acting restrictions that had been 
imposed a few years earlier. But it 
was in the cases of infants and 
pregnant women that exception-
alism was most directly chal-
lenged. Some pediatricians as-
serted that babies had a “right to 
be tested” because, if infected, 
they required vigilant medical care 
before they became sick — a right 
that trumped the mother’s right to 
privacy, which would be breached 
by the discovery of maternal anti-
body in the newborn. Ultimately, 
two states — New York and Con-
necticut — enacted statutes man-
dating HIV testing in newborns.
More sustained were the efforts 
that followed the 1994 discovery 
that administering zidovudine dur-
ing pregnancy could reduce the 
rate of vertical transmission by 
two thirds. In 1996, the House of 
Delegates of the American Medi-
cal Association passed a resolution 
recommending mandatory test-
ing of pregnant women. Although 
such moves stalled, efforts to loos-
en the consent requirements for 
pregnant women gained traction. 
In 1998, the Institute of Medicine 
(IOM) recommended the routine 
testing of all pregnant women in 
the United States, calling for a 
shift from stringent consent to an 
informed right of refusal.3 A year 
later, the American Academy of 
Pediatrics and the American Col-
lege of Obstetricians and Gyne-
cologists jointly endorsed univer-
sal opt-out screening for pregnant 
women. When the CDC consid-
ered these recommendations in 
2001, it endorsed universal screen-
ing of pregnant women.4 But 
while calling for a simplified “pre-
test process,” eliminating time-
consuming counseling, it did not 
explicitly recommend an opt-out 
approach.4,5 
By 2004, according to the Kaiser 
Family Foundation, four states — 
Texas, Michigan, Tennessee, and 
Arkansas — required the testing 
of pregnant women unless they 
refused. In 13 states — including 
California, Florida, New Jersey, and 
Maryland — providers were re-
quired to offer pregnant women 
testing. Thus, the changes being 
proposed by the CDC and in New 
York grow out of more than a de-
cade of efforts to loosen the stric-
tures of HIV exceptionalism.
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The move to make testing more 
routinely available, or even to re-
quire that physicians offer it to 
patients, has encountered little op-
position. But there is resistance to 
the elimination of pretest counsel-
ing and specific written consent, 
as well as to the adoption of an 
opt-out standard. Although Frie-
den rejects mandatory HIV test-
ing, many fear that without a re-
quirement for written consent, 
testing would in effect become 
compulsory. “This is not informed 
consent, and it is not even con-
sent,” said one activist. It is rath-
er an attempt “to ram HIV testing 
down people’s throats without 
their permission.”
According to advocates of 
change, the transformation of HIV 
disease into a complex chronic 
condition requiring long-term, on-
going clinical management means 
that the limits imposed when 
medicine had little to offer have 
outlived their justification. Pro-
ponents argue that prevailing re-
quirements impede wide-scale 
testing because they are burden-
some and time-consuming. Fur-
thermore, they relieve physicians 
of an obligation to offer testing. 
Less often acknowledged is the 
fact that an opt-out approach shifts 
the burden from those who would 
choose to undergo the test to 
those who would refuse.
Making it more difficult to 
say no may be justified by public 
health considerations, particularly 
by concern about preventable op-
portunistic infections in persons 
who are unaware of their HIV in-
fection and about transmission 
to their sexual or needle-sharing 
partners. As state and local health 
policymakers consider the new 
CDC recommendations, it will be 
crucial that the assumptions — 
both spoken and unspoken — in-
forming the new testing paradigm 
be the subject of open, ethically 
informed, and evidence-based dis-
cussion.
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Getting Serious about Cholera
David A. Sack, M.D., R. Bradley Sack, M.D., Sc.D., and Claire-Lise Chaignat, M.D., M.P.H.
Deaths from cholera are again making news, this time in 
Angola. According to the World 
Health Organization (WHO), An-
gola had reported 46,758 cases 
of cholera, including 1893 deaths, 
as of June 19, 2006.1 The outbreak 
has affected 14 of 18 provinces, 
but nearly half the cases were re-
ported in the coastal capital, Lu-
anda, and another 17 percent in 
Benguela provinces. The overall 
case fatality rate is about 4 per-
cent, although in some provinces, 
it has reached 30 percent. This 
outbreak represents another in a 
series of cholera epidemics in this 
country,2 which is among the 
poorest in the world and is still 
recovering from years of armed 
conflict. Several other African 
countries have also had recent 
outbreaks (see map), in the sev-
enth pandemic of cholera caused 
by Vibrio cholerae O1 El Tor, which 
reached Africa in 1970.
In addition to the reported cas-
es, many are either not reported 
or are labeled as “acute watery di-
arrhea.” Although 94 percent of 
the 101,383 cholera cases and 99 
percent of the 2345 related deaths 
registered with the WHO in 2004 
occurred in sub-Saharan Africa, 
these numbers present a mislead-
ing picture of the global cholera 
burden. V. cholerae infects persons 
in many developing countries, 
with the highest rates in Asia, but 
many Asian countries do not re-
port their cases because of the ef-
fects on trade and travel, however 
unwarranted. The true burden is 
probably several million cases in 
Asia and Africa, with fewer cases 
in Latin America. Assuming a case 
fatality rate of 4 percent (on the 
basis of treated cases), annual 
mortality of at least 40,000 to 
100,000 is probable, and even this 
may be an underestimation: since 
many patients die before reaching 
a health care facility, the true 
number of deaths may be much 
higher.
In the 21st century, we know 
a great deal about cholera — its 
ecology, transmission patterns 
through contaminated water, and 
pathophysiology.3 Simple, inex-
pensive rehydration treatment is 
nearly 100 percent successful, and 
safe oral vaccines can prevent most 
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